Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New dual mTOR/PI3K-alpha inhibitor PF-04979064 may advance to clinic as anticancer agent

Sep. 14, 2010

FDA approves new 500-mg dose of Faslodex

Sep. 13, 2010

Debiopharm and Aurigene nominate Debio-0617 as development candidate

Sep. 13, 2010

Regeneron provides update on trials of aflibercept in metastatic colorectal cancer

Sep. 13, 2010

Bayer Schering claims new hepatocyte growth factor receptor inhibitors

Sep. 13, 2010

Phase III COU-AA-301 trial of abiraterone/prednisone is unblinded due to efficacy

Sep. 10, 2010

Tragara Pharma begins phase I TG-02 trial in hematological malignancies

Sep. 10, 2010

Boehringer Ingelheim presents new C-raf inhibitors

Sep. 10, 2010

GSK and Genmab initiate phase III trial of ofatumumab in indolent B-NHL

Sep. 10, 2010

Yondelis obtains marketing authorization for ovarian cancer in Russia

Sep. 10, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...